National Institutes of Health, 8153-8154 [2013-02480]
Download as PDF
Federal Register / Vol. 78, No. 24 / Tuesday, February 5, 2013 / Notices
The annualized cost to respondents is
estimated at $308,218, assuming
respondents time at the rate of $22 per
hour and healthcare provider time at the
rate of $53 per hour. There are no
Capital Costs to report. There are no
Operating or Maintenance Costs to
report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Ms. Shari Eason
Ludlam, MPH, Project Officer, NIH,
NHLBI, 6701 Rockledge Drive, MSC
7913, Bethesda, MD 20892–7934, or call
non-toll-free number 301–402–2900 or
Email your request, including your
address to: Ludlams@nhlbi.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT:
Dated: January 25, 2013.
Michael Lauer,
Director, Division of Cardiovascular Sciences,
National Heart, Lung, and Blood Institute,
National Institutes of Health.
tkelley on DSK3SPTVN1PROD with NOTICES
Dated: January 28, 2013.
Lynn W. Susulske,
Government Information Specialist. Freedom
of Information and Privacy Act Branch,
NHLBI, National Institutes of Health.
[FR Doc. 2013–02505 Filed 2–4–13; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
18:46 Feb 04, 2013
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request: Recipient Epidemiology and
Donor Evaluation Study-III (REDS–III)
Request for Generic Clearance
Summary: Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Heart, Lung, and Blood Institute
(NHLBI), the National Institutes of
Health (NIH) has submitted to the Office
of Management and Budget (OMB) a
request for review and approval the
information collection listed below.
This proposed information collection
was previously published in the Federal
Register in Volume 77, No. 199/
Monday, October 15, 2012, pages
62518–62519, and allowed 60-days for
public comment. No comments have
been received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Institutes of Health may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
Proposed Collection: Title: Recipient
Epidemiology and Donor Evaluation
Study-III (REDS–III). Type of
Information Collection Request: New.
Need and Use of Information Collection:
The objective of the Recipient
Epidemiology and Donor Evaluation
Study-III (REDS–III) program is to
ensure safe and effective blood banking
and transfusion medicine practices
through a comprehensive, multifaceted
strategy involving basic, translational,
and clinical research to improve the
benefits of transfusion while reducing
its risks. The conduct of epidemiologic,
survey, and laboratory studies is the
cornerstone of REDS–III and its
predecessors, the REDS and REDS–II
programs. Over the past 20 years, the
National Heart, Lung, and Blood
Institute (NHLBI) REDS programs have
proven to be the premier research
programs in blood collection and
transfusion safety in the United States.
Successive renditions of the REDS
programs have built upon the many
successes that this research network has
realized over the years while being
responsive to changing research and
clinical needs, and adapting to emerging
priorities. Research findings have served
to improve the screening of donors and
collected blood products, blood banking
practices, diagnoses, and the basic
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
8153
science principles of transfusion
medicine.
While significant progress has been
made, transfusion therapy—a very
commonly used therapy affecting about
six million recipients annually in the
U.S.—remains one of the least
understood medical procedures. REDS–
II conducted studies of blood donor
health but much more needs to be
learned, including how donor genetic or
environmental factors may affect the
quality of collected blood components
and influence non-infectious
transfusion complications in recipients.
Additionally, there is always the
potential that a new, emerging or reemerging infection may pose a threat to
the safety of the U.S. blood supply.
Much of the success of the REDS
programs was due to their ability to
respond in a timely fashion to potential
blood safety threats such as West Nile
Virus (WNV) in 2002 or Xenotropic
Murine Leukemia Virus Related Virus
(XMRV) in 2009. Globally, the threat of
HIV and other blood-borne infections to
blood safety remains real and has to be
closely monitored. Therefore,
continuing collection of new scientific
evidence through REDS–III is both
critical to public health in the U.S. and
to countries struggling with the HIV
epidemic where blood safety and
availability are major concerns.
Additionally, the research areas
encompassed in REDS–III have been
and continue to be hypothesis
generating, leading to the development
of new basic and translational research
projects with implications well beyond
the fields of blood banking and
transfusion medicine. REDS–III has also
been charged with the tasks of
education and training and integration
of these components in a transfusion
medicine research network.
With this submission, the REDS–III
Study seeks approval from OMB to
develop research studies with data
collection activities using focus groups,
cognitive interviews, questionnaires
and/or qualitative interviews following
all required informed consent
procedures for respondents and parents/
caregivers as appropriate. With this
generic clearance, study investigators
will be able to use the OMB-approved
data collection methods where
appropriate to plan and implement time
sensitive studies. Such studies that fall
within the overall scope of this
submission will be subjected to
expedited review and approval by OMB
before their implementation.
Additionally, studies are reviewed by an
NHLBI Observational Study Monitoring
Board (OSMB) and by all relevant IRBs.
E:\FR\FM\05FEN1.SGM
05FEN1
8154
Federal Register / Vol. 78, No. 24 / Tuesday, February 5, 2013 / Notices
Frequency of Response: Once.
Affected Public: Individuals. Type of
Respondents: Males and females 16
years old or older. The annual reporting
burden is as follows: Estimated Number
of Respondents: 6,882; Estimated
Number of Responses per Respondent:
Focus Groups: 1 per respondent;
Cognitive Interviews: 2 per respondent;
Respondent Surveys: 3 per respondent.
Average Burden of Hours per Response:
Focus Groups: 1.5 hours per respondent;
Cognitive Interviews: 1 hour per
respondent; Respondent Surveys: 20
minutes per respondent Estimated Total
Annual Burden Hours Requested: 7,532.
The annualized total costs to all
respondents are $66,288. There are no
Capital Costs to report. There are no
Operating or Maintenance Costs to
report.
ESTIMATED BURDEN HOURS FOR PROPOSED EXAMPLE STUDIES TO BE CONDUCTED UNDER THIS CLEARANCE
Annual
frequency
per response
Number of
respondents
Type of collection
Hours per
response
Total hours
300
500
6,082
1
2
3
1.5
1.0
.33
450
1,000
6,082
Total ........................................................................................................
tkelley on DSK3SPTVN1PROD with NOTICES
Focus Groups ................................................................................................
Cognitive Interviews .......................................................................................
Respondent Surveys .....................................................................................
6,882
........................
..........................
7,532
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and the assumptions used;
(3) Ways to enhance the quality, utility,
and clarity of the information collected;
and (4) Ways to minimize the burden of
the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments To OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: Simone
Glynn, MD, Project Officer/ICD Contact,
Two Rockledge Center, Suite 9142, 6701
Rockledge Drive, Bethesda, MD 20892,
or call 301–435–0065, or Email your
request to: glynnsa@nhlbi.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
VerDate Mar<15>2010
17:18 Feb 04, 2013
Jkt 229001
Dated: January 13, 2013.
Keith Hoots,
Director, Division of Blood Diseases and
Resources, National Heart, Lung, and Blood
Institute, NIH.
Dated: January 13, 2013.
Lynn Susulske,
NHLBI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2013–02480 Filed 2–4–13; 8:45 am]
BILLING CODE 4141–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Comment: Input on
Recommendations from the Council of
Councils Working Group on Use of
Chimpanzees in NIH-Supported
Research
The National Institutes of
Health (NIH) Council of Councils
received and adopted the
recommendations and Report of the NIH
Council of Councils Working Group on
the Use of Chimpanzees in NIHSupported Research on January 22,
2013. The report is posted on the NIH
Web site at https://dpcpsi.nih.gov/
council/working_group_message.aspx.
The agency will consider the
recommendations contained in the
report as the agency formulates policy.
The NIH also announces the opening of
a Request for Comment (RFC) period to
collect input on the recommendations
from interested parties. Comments will
be accepted until Saturday, March 23,
2013, via the comment database at
https://grants.nih.gov/grants/rfi/
rfi.cfm?ID=31. In the interim, NIH will
continue to apply its policy on Research
Involving Chimpanzees (see NOT–OD–
12–025; https://grants.nih.gov/grants/
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Responses to this RFC will be
accepted through 11:59 p.m. EST
Saturday, March 23, 2013.
DATES:
All comments should be
submitted electronically to https://
grants.nih.gov/grants/rfi/rfi.cfm?ID=31.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
The
Division of Program Coordination,
Planning, and Strategic Initiatives,
Office of the Director, National
Institutes of Health at
dpcpsi@od.nih.gov.
The use of
animals in biomedical and behavioral
research has enabled scientists to
identify new ways to treat illness,
extend life, and improve health and
well-being. Chimpanzees are our closest
relatives in the animal kingdom,
providing exceptional insights into
human biology and requiring special
consideration and respect. While used
very selectively and in limited numbers
for biomedical research, chimpanzees
have served an important role in
advancing human health in the past.
However, new methods and
technologies developed by the
biomedical community have provided
alternatives to the use of chimpanzees
in several areas of research.
In December 2010, the NIH
commissioned a study by the Institute of
Medicine (IOM) to assess whether
chimpanzees are or will be necessary for
NIH-funded biomedical and behavioral
research. A year later on December 15,
2011, the IOM issued its findings, with
a primary recommendation that the use
of chimpanzees in research be guided by
a set of principles and criteria. The
committee proposed three principles to
analyze current and potential future
research using chimpanzees:
SUPPLEMENTARY INFORMATION:
National Institutes of Health
SUMMARY:
guide/notice-files/NOT–OD–12–
025.html.)
E:\FR\FM\05FEN1.SGM
05FEN1
Agencies
[Federal Register Volume 78, Number 24 (Tuesday, February 5, 2013)]
[Notices]
[Pages 8153-8154]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02480]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request: Recipient Epidemiology and
Donor Evaluation Study-III (REDS-III) Request for Generic Clearance
Summary: Under the provisions of Section 3507(a)(1)(D) of the
Paperwork Reduction Act of 1995, the National Heart, Lung, and Blood
Institute (NHLBI), the National Institutes of Health (NIH) has
submitted to the Office of Management and Budget (OMB) a request for
review and approval the information collection listed below. This
proposed information collection was previously published in the Federal
Register in Volume 77, No. 199/Monday, October 15, 2012, pages 62518-
62519, and allowed 60-days for public comment. No comments have been
received. The purpose of this notice is to allow an additional 30 days
for public comment. The National Institutes of Health may not conduct
or sponsor, and the respondent is not required to respond to, an
information collection that has been extended, revised, or implemented
on or after October 1, 1995, unless it displays a currently valid OMB
control number.
Proposed Collection: Title: Recipient Epidemiology and Donor
Evaluation Study-III (REDS-III). Type of Information Collection
Request: New. Need and Use of Information Collection: The objective of
the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)
program is to ensure safe and effective blood banking and transfusion
medicine practices through a comprehensive, multifaceted strategy
involving basic, translational, and clinical research to improve the
benefits of transfusion while reducing its risks. The conduct of
epidemiologic, survey, and laboratory studies is the cornerstone of
REDS-III and its predecessors, the REDS and REDS-II programs. Over the
past 20 years, the National Heart, Lung, and Blood Institute (NHLBI)
REDS programs have proven to be the premier research programs in blood
collection and transfusion safety in the United States. Successive
renditions of the REDS programs have built upon the many successes that
this research network has realized over the years while being
responsive to changing research and clinical needs, and adapting to
emerging priorities. Research findings have served to improve the
screening of donors and collected blood products, blood banking
practices, diagnoses, and the basic science principles of transfusion
medicine.
While significant progress has been made, transfusion therapy--a
very commonly used therapy affecting about six million recipients
annually in the U.S.--remains one of the least understood medical
procedures. REDS-II conducted studies of blood donor health but much
more needs to be learned, including how donor genetic or environmental
factors may affect the quality of collected blood components and
influence non-infectious transfusion complications in recipients.
Additionally, there is always the potential that a new, emerging or re-
emerging infection may pose a threat to the safety of the U.S. blood
supply. Much of the success of the REDS programs was due to their
ability to respond in a timely fashion to potential blood safety
threats such as West Nile Virus (WNV) in 2002 or Xenotropic Murine
Leukemia Virus Related Virus (XMRV) in 2009. Globally, the threat of
HIV and other blood-borne infections to blood safety remains real and
has to be closely monitored. Therefore, continuing collection of new
scientific evidence through REDS-III is both critical to public health
in the U.S. and to countries struggling with the HIV epidemic where
blood safety and availability are major concerns. Additionally, the
research areas encompassed in REDS-III have been and continue to be
hypothesis generating, leading to the development of new basic and
translational research projects with implications well beyond the
fields of blood banking and transfusion medicine. REDS-III has also
been charged with the tasks of education and training and integration
of these components in a transfusion medicine research network.
With this submission, the REDS-III Study seeks approval from OMB to
develop research studies with data collection activities using focus
groups, cognitive interviews, questionnaires and/or qualitative
interviews following all required informed consent procedures for
respondents and parents/caregivers as appropriate. With this generic
clearance, study investigators will be able to use the OMB-approved
data collection methods where appropriate to plan and implement time
sensitive studies. Such studies that fall within the overall scope of
this submission will be subjected to expedited review and approval by
OMB before their implementation. Additionally, studies are reviewed by
an NHLBI Observational Study Monitoring Board (OSMB) and by all
relevant IRBs.
[[Page 8154]]
Frequency of Response: Once. Affected Public: Individuals. Type of
Respondents: Males and females 16 years old or older. The annual
reporting burden is as follows: Estimated Number of Respondents: 6,882;
Estimated Number of Responses per Respondent: Focus Groups: 1 per
respondent; Cognitive Interviews: 2 per respondent; Respondent Surveys:
3 per respondent. Average Burden of Hours per Response: Focus Groups:
1.5 hours per respondent; Cognitive Interviews: 1 hour per respondent;
Respondent Surveys: 20 minutes per respondent Estimated Total Annual
Burden Hours Requested: 7,532. The annualized total costs to all
respondents are $66,288. There are no Capital Costs to report. There
are no Operating or Maintenance Costs to report.
Estimated Burden Hours for Proposed Example Studies To Be Conducted Under This Clearance
----------------------------------------------------------------------------------------------------------------
Annual
Type of collection Number of frequency per Hours per Total hours
respondents response response
----------------------------------------------------------------------------------------------------------------
Focus Groups.................................... 300 1 1.5 450
Cognitive Interviews............................ 500 2 1.0 1,000
Respondent Surveys.............................. 6,082 3 .33 6,082
---------------------------------------------------------------
Total....................................... 6,882 .............. .............. 7,532
----------------------------------------------------------------------------------------------------------------
Request for Comments: Written comments and/or suggestions from the
public and affected agencies should address one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the function of the agency,
including whether the information will have practical utility; (2) The
accuracy of the agency's estimate of the burden of the proposed
collection of information, including the validity of the methodology
and the assumptions used; (3) Ways to enhance the quality, utility, and
clarity of the information collected; and (4) Ways to minimize the
burden of the collection of information on those who are to respond,
including the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology.
Direct Comments To OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974,
Attention: Desk Officer for NIH. To request more information on the
proposed project or to obtain a copy of the data collection plans and
instruments, contact: Simone Glynn, MD, Project Officer/ICD Contact,
Two Rockledge Center, Suite 9142, 6701 Rockledge Drive, Bethesda, MD
20892, or call 301-435-0065, or Email your request to:
glynnsa@nhlbi.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30 days
of the date of this publication.
Dated: January 13, 2013.
Keith Hoots,
Director, Division of Blood Diseases and Resources, National Heart,
Lung, and Blood Institute, NIH.
Dated: January 13, 2013.
Lynn Susulske,
NHLBI Project Clearance Liaison, National Institutes of Health.
[FR Doc. 2013-02480 Filed 2-4-13; 8:45 am]
BILLING CODE 4141-01-P